Hematology

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Celgene) ACE-536-MDS-002 / COMMANDSA Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell TransfusionsLeber, Dr BrianOpen to recruitmentNCT03682536
(Constellation) CPI-0610-02 / MANIFEST studyA Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)Leber, Dr BrianOpen to recruitmentNCT02158858
(Janssen) 54179060CLL3011 / GLOWA Randomized, Open-label Phase 3 study of the Combination of Ibrutinib plus Venetoclax
versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic
Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Fraser, Dr GraemeOpen to recruitmentNCT03462719
(Novartis) CINC424D2301 / REACH 3A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH 3)Leber, Dr BrianOpen to recruitmentNCT03112603
(Roche) GO39942 / POLARIXA PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMAKouroukis, Dr TomOpen to recruitmentNCT03274492
(UHN) SMART-AML-001Feasibility and validation study of the LSC17 score in acute myeloid leukemia (AML) patientsLeber, Dr BrianOpen to recruitment
(CCTG) LY.17A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaFraser, Dr GraemeSuspended/On holdNCT02436707
(UHN) CFI-400945-CL-002An Open-Label, Dose Escalation, Safety and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeLeber, Dr BrianSuspended/On holdNCT03187288
Download PDF